A factor contributing to the disparate results is most likely the underlying heterogeneity of bladder cancer and the lack of adequate molecular descriptions of bladder cancer molecular subtypes; the context in which the ERBB2 and EGFR targets operate. Here, ERBB2 is linked to urinary bladder carcinoma.